



**ITEM 8.01 - OTHER EVENTS**

On January 25, 2006, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) notified ImmunoGen, Inc. (Nasdaq: IMGN) that as part of its ongoing portfolio management process and based on the evaluation of recent clinical data in the context of other opportunities in its pipeline, Millennium had decided not to continue the development of its MLN2704 compound. MLN2704 consists of a Millennium antibody to the Prostate-Specific Membrane Antigen (PSMA) and ImmunoGen's DM1 and was in development by Millennium under a 2001 agreement that gave Millennium rights to use ImmunoGen's maytansinoid Tumor-Activated Prodrug (TAP) technology with antibodies targeting PSMA. On January 26, 2006, Millennium publicly disclosed that it had discontinued development of MLN2704 and that it was in the process of evaluating whether to continue development of this antibody conjugated with other cell-killing agents including other maytansinoids. Millennium retains its right to use ImmunoGen's maytansinoid TAP technology with antibodies targeting PSMA.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**

(Registrant)

Date: January 26, 2006

/s/ Karleen M. Oberton

Karleen M. Oberton  
Senior Corporate Controller  
(Principal Accounting Officer)

